Skip to content
PICO Portalanswers from OpenAlex

Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions

PaperCitations, authors & open-access status

Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions is a paper indexed in PICO Portal from OpenAlex.

How many citations does Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions have?

PICO Portalcitation count

Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions has 96 citations in the OpenAlex counts PICO Portal stores.

When was Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions published?

PICO Portalyear

Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions has 2022 year in the PICO Portal index.

What is the open-access status of Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions?

PICO Portaloa status

Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions has hybrid oa status in the PICO Portal index.

What is the DOI of Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions?

PICO Portaldoi

The DOI for Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions is on the source record.

What is the PMID of Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions?

PICO Portalpmid

The PMID for Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions is on the source record.

What is the OpenAlex record for Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions?

PICO Portalopenalex

The OpenAlex for Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions is on the source record.

Related on PICO Portal

470M+ articles · 14-day free trial